Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: LMT stock price vs LLY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LLY's multiple
Needs Annual EPS, LLY P/E.
Implied fair value · at LMT's multiple
Needs LMT P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
LOCKHEED MARTIN CORP · implied price per share
Reporting currency could not be verified.
ELI LILLY AND COMPANY · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
LMT · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
BOEING CO
LMT vs BA
NORTHROP GRUMMAN CORP /DE/
LMT vs NOC
TEXTRON INC
LMT vs TXT
HUNTINGTON INGALLS INDUSTRIES, INC.
LMT vs HII
AXON ENTERPRISE, INC.
LMT vs AXON
Howmet Aerospace Inc.
LMT vs HWM
Pfizer Inc.
LMT vs PFE
Merck & Co., Inc.
LMT vs MRK
Johnson & Johnson
LMT vs JNJ
AbbVie Inc.
LMT vs ABBV
Amgen Inc.
LMT vs AMGN
Bristol-Myers Squibb Company
LMT vs BMY
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe LMT can sustain its current profitability and improve growth without a major re-rating penalty, then holding or selectively adding makes sense because LMT is cheaper than LLY on headline multiples but already trades above its DCF range and near the top of its historical band.
LMT trades at $523.78 versus an implied LLY-multiple price of $1059.46, suggesting 102.3% upside on the P/E framework, but this comparison is distorted by LLY’s much higher growth and valuation multiples. On absolute valuation, LMT sits above the top of its DCF range and near the upper end of its historical band, implying the stock is not obviously cheap on a standalone basis.
Supporting Metrics
